gasdermin Inhibitors

Chemical inhibitors of gasdermin target various points within the signaling pathways that are crucial for the protein's function. Disulfiram operates by forming adducts with cysteine residues within proteins. Since gasdermin contains cysteine residues that are essential for its pore-forming function, disulfiram's covalent modification of these residues disrupts gasdermin's structure and prevents it from executing its role in pyroptosis. Similarly, Bay 11-7082 inhibits the NF-κB pathway, which is instrumental in the regulation of inflammatory cytokines that induce gasdermin activation. By blocking NF-κB, Bay 11-7082 indirectly hinders the pathways leading to gasdermin activation. NSC 23766 interferes with Rac1 GTPase, impacting actin cytoskeleton reorganization. This disruption can impair the proper localization or function of gasdermin, thus inhibiting its activity. Z-VAD-FMK, a pan-caspase inhibitor, prevents the cleavage of gasdermin by caspases, which is a necessary step for its activation, thereby preventing gasdermin from becoming active and forming pores in the cell membrane.

Further, Necrosulfonamide inhibits MLKL, a crucial protein in necroptosis, a pathway that shares components with the gasdermin-mediated pyroptosis pathway. Inhibition of MLKL can interrupt the signaling required for gasdermin activation. CA-074 Me, as a cathepsin B inhibitor, blocks the release of cathepsins which can contribute to inflammasome activation, an upstream event necessary for gasdermin action. GSK'872 and MCC950 target RIPK3 and the NLRP3 inflammasome, respectively, both of which are upstream of gasdermin activation. By inhibiting these molecules, they prevent the subsequent activation of gasdermin. VX-765, another caspase-1 inhibitor, directly inhibits gasdermin by halting its maturation. YVAD-cmk also works by inhibiting the cleavage of gasdermin, thus blocking its oligomerization and pore formation. Lastly, TAK-242 selectively inhibits TLR4 signaling, which is involved in activating caspase-1 and NLRP3 inflammasome, thereby indirectly inhibiting the activation of gasdermin.